Circulating Microbial Signatures and Cardiovascular Death in Patients With ESRD

被引:13
|
作者
Sumida, Keiichi [1 ]
Pierre, Joseph F. [2 ,3 ]
Han, Zhongji [1 ]
Mims, Tahliyah S. [2 ]
Potukuchi, Praveen Kumar [1 ]
Yuzefpolskaya, Melana [4 ]
Colombo, Paolo C. [4 ]
Demmer, Ryan T. [5 ,6 ]
Datta, Susmita [7 ]
Kovesdy, Csaba P. [1 ,8 ]
机构
[1] Univ Tennessee, Dept Med, Div Nephrol, Hlth Sci Ctr, 956 Court Ave,Suite A220, Memphis, TN 38163 USA
[2] Univ Tennessee, Coll Med, Dept Pediat, Hlth Sci Ctr, Memphis, TN 38163 USA
[3] Univ Tennessee, Coll Med, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA
[4] Columbia Univ, New York Presbyterian Hosp, Dept Med, Div Cardiol, New York, NY USA
[5] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA
[6] Columbia Univ, Mailman Sch Publ Hlth, Div Epidemiol, New York, NY USA
[7] Univ Florida, Dept Biostat, Gainesville, FL USA
[8] Memphis VA Med Ctr, Nephrol Sect, Memphis, TN USA
来源
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 10期
基金
美国国家卫生研究院;
关键词
cardiovascular disease; chronic kidney disease; circulating microbiome; end-stage renal disease; inflammation; mortality; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; BACTERIAL-DNA; SYSTEMIC INFLAMMATION; KAPPA-B; BLOOD; NRF2; ATHEROSCLEROSIS; ASSOCIATION; ENDOTOXIN;
D O I
10.1016/j.ekir.2021.07.023
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Patients with end-stage renal disease (ESRD) experience disproportionately high cardiovascular morbidity and mortality. Accumulating evidence suggests a role for the circulating microbiome in the pathogenesis of cardiovascular disease; however, little is known about its association with premature cardiovascular mortality in ESRD. Methods: In a pilot case-control study of 17 hemodialysis patients who died of a cardiovascular event and 17 matched hemodialysis controls who remained alive during a median follow-up of 2.0 years, we compared the levels and composition of circulating microbiome, including Bacteria, Archaea, and Fungi, in serum samples by quantitative polymerase chain reaction and 16S or Internal Transcribed Spacer (ITS) ribosomal RNA (rRNA) sequencing, respectively. Associations of the circulating cell-free microbial signatures with clinical parameters and cardiovascular death were examined using the Spearman rank correlation and multivariable conditional logistic regression, respectively. Results: Both 16S and ITS rRNA were detectable in all (except 3 for ITS) examined patients' serum samples. Despite no significant difference in 16S rRNA levels and alpha diversity between cases and controls, taxonomic analysis demonstrated differential community membership between groups, with significantly greater Actinobacteria and less Proteobacteria observed in cases than in controls at the phylum level. Proportions of Actinobacteria and Proteobacteria phyla were significantly correlated with plasma nuclear factor erythroid 2-related factor 2 (Nrf2) levels (rho =-0.41 and 0.42, P = 0.015 and 0.013, respectively) and marginally associated with risk of cardiovascular death (adjusted odds ratios [95% confidence intervals] = 1.12 [0.98-1.29] and 0.88 [0.76-1.02] for 1% increase, respectively). Conclusion: Alterations of the circulating cell-free microbial signatures may be associated with higher premature cardiovascular mortality in ESRD.
引用
收藏
页码:2617 / 2628
页数:12
相关论文
共 50 条
  • [31] Cardiovascular disease and mortality in ESRD
    Foley, RN
    Parfrey, PS
    JOURNAL OF NEPHROLOGY, 1998, 11 (05) : 239 - 245
  • [32] New circulating biomarkers for predicting cardiovascular death in healthy population
    Melander, Olle
    Modrego, Javier
    Zamorano-Leon, Jose J.
    Santos-Sancho, Juana M.
    Lahera, Vicente
    Lopez-Farre, Antonio J.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2015, 19 (10) : 2489 - 2499
  • [33] Circulating miRNAs signatures in patients with various asthma phenotypes
    Kowalski, M. L.
    Makowska, J. S.
    Pawelczyk, M.
    Wardzynska, A.
    Piechota-Polanczyk, A.
    Niedzielska, T.
    ALLERGY, 2015, 70 : 223 - 223
  • [34] Does kidney transplantation halt cardiovascular disease progression in patients with ESRD?
    Meier-Kriesche, HU
    Schold, JD
    Srinivas, TR
    Reed, AI
    Kaplan, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 261 - 261
  • [35] Periodontal disease: a modifiable risk factor for cardiovascular disease in ESRD patients?
    Madore, Francois
    KIDNEY INTERNATIONAL, 2009, 75 (07) : 672 - 674
  • [36] Increased risk of death in pediatric and adult patients with ESRD secondary to lupus
    Sule, Sangeeta
    Fivush, Barbara
    Neu, Alicia
    Furth, Susan
    PEDIATRIC NEPHROLOGY, 2011, 26 (01) : 93 - 98
  • [37] Increased risk of death in pediatric and adult patients with ESRD secondary to lupus
    Sangeeta Sule
    Barbara Fivush
    Alicia Neu
    Susan Furth
    Pediatric Nephrology, 2011, 26 : 93 - 98
  • [38] CHANGES IN CAUSES OF DEATH AMONG ESRD PATIENTS IN THE UNITED-STATES
    PORT, FK
    GARCIA, JR
    WHELTON, P
    FITZSIMMONS, SC
    MOULTON, LH
    KIDNEY INTERNATIONAL, 1990, 37 (01) : 283 - 283
  • [39] Optimal Cardiovascular Therapy for Patients with ESRD over the Next Several Years
    Henrich, William L.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 : S106 - S109
  • [40] Does reduction in cardiovascular death account for the increase in ESRD? An examination of the 'competing mortality' hypothesis.
    Levy, EM
    Meltzer, D
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0733 - A0733